Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Brain metastases from solid tumors are diagnosed in more than 300,000 patients annually. Nonsmall cell lung cancer accounts for the majority of CNS mets. Treatment with whole brain radiation and steroids will improve neurologic symptoms in about 50% of patients although survival is short. This study will test the safety and efficacy of temozolomide in combination with radiation therapy in the treatment of patients with brain mets form nonsmall cell lung cancer.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histologic confirmation of non-small-cell lung cancer
Stable systemic disease
Maximum of one prior chemotherapy regimen for metastatic systemic disease
Radiotherapy for local control or palliative bony lesions is allowed
Karnofsky of greater than or equal to 70%
Adequate hematologic, renal and liver function
Patients eligible for surgery of the brain
Any previous chemotherapy for the brain metastasis
Chemotherapy within 4 weeks or previous temozolomide
Prior radiotherapy to the brain
Radiation therapy to greater than 50% of the bone marrow
Insufficient recovery from previous therapies
Active nonmalignant systemic disease
Inability to take oral medication
Pregnant or nursing women
Non use of adequate contraceptive techniques, negative urine pregnancy test is required
Central Nervous System Neoplasms
Nervous System Neoplasms
Central Nervous System Diseases
Nervous System Diseases
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action